Business Standard

Pfizer's Covid vaccine price hike seen giving revenue boost for yrs: Report

Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set

Pfizer vaccine,
Premium

Reuters
Pfizer's plan to as much as quadruple current U.S. prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said.
 
The drugmaker, which developed and sells the vaccine with Germany's BioNTech said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.
 
Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set.
 
Wells Fargo analyst Mohit Bansal said the new pricing

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 21 2022 | 9:03 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com